{"id":"elucirem-gadopiclenol","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gadopiclenol is a macrocyclic gadolinium chelate complex designed for use as an MRI contrast agent. It distributes in the extracellular space and increases signal intensity in T1-weighted MRI images by paramagnetic effects on nearby water molecules, improving visualization of tissue perfusion and anatomy. The macrocyclic structure provides enhanced stability and safety compared to linear gadolinium agents.","oneSentence":"Gadopiclenol is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening T1 relaxation time of water protons in tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:40:19.005Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"MRI contrast enhancement for diagnostic imaging of the central nervous system and body"}]},"trialDetails":[{"nctId":"NCT07492121","phase":"PHASE2","title":"Screening for Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"University of Zurich","startDate":"2026-09","conditions":"Lung Cancer Stage IV, Melanoma Stage IV, Breast Cancer Metastatic","enrollment":180},{"nctId":"NCT06057168","phase":"PHASE3","title":"Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas","status":"COMPLETED","sponsor":"Guerbet","startDate":"2023-09-07","conditions":"Brain Tumor, Primary, Brain Tumor, Recurrent","enrollment":138},{"nctId":"NCT05590884","phase":"PHASE2","title":"Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age","status":"COMPLETED","sponsor":"Guerbet","startDate":"2022-09-21","conditions":"Central Nervous System Diseases, Pediatric Disorder, Body Indication","enrollment":36},{"nctId":"NCT06226129","phase":"PHASE4","title":"Gadopiclenol in Contrast Enhanced MRI of the Prostate","status":"RECRUITING","sponsor":"Columbia University","startDate":"2024-02-14","conditions":"Prostate Cancer","enrollment":150},{"nctId":"NCT05954559","phase":"PHASE4","title":"High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-08-01","conditions":"Myocardial Fibrosis","enrollment":25},{"nctId":"NCT06846853","phase":"PHASE4","title":"Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging)","status":"RECRUITING","sponsor":"UConn Health","startDate":"2025-03-01","conditions":"Contrast Enhanced Images vs. Non-contrast Images, Gadopiclinol Enhanced Images vs. Gadobutrol Enhanced Images","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":53,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Elucirem (Gadopiclenol)","genericName":"Elucirem (Gadopiclenol)","companyName":"Johns Hopkins University","companyId":"johns-hopkins-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gadopiclenol is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening T1 relaxation time of water protons in tissues. Used for MRI contrast enhancement for diagnostic imaging of the central nervous system and body.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}